Document:

hrmy-ex1020_1164.htm

Exhibit10.20

 

September 7th , 2017

 

Jeffrey Dierks

428 W. 5th Avenue

Conshohocken, PA 19428

 

Dear Jeff:

 

On behalf of Harmony Biosciences, LLC (“Harmony Biosciences” or the “Company”), I am pleased to extend an offer of employment with the Company as Vice President, Marketing.  Except for business travel on behalf of the Company, you will work out of the Company’s Philadelphia Regional Office and other Company venues.  This position will report to the Chief Commercial Officer or his designee.

 

Your start date will be mutually determined but we anticipate it to be on or around October 2, 2017.  We are excited about the possibility of you joining our team at Harmony Biosciences and hope you will accept our offer to join us in executing our growth plans for the Company.

 

The terms of your employment offer are outlined below:

	
 
	
•
	
Bi-monthly base pay of $10,417 which, when annualized, is equivalent to a base salary of $250,000 per year.

	
 
	
•
	
Participation (pro-rated for the calendar year in which your actual start date occurs) in the Harmony Biosciences, LLC Performance Bonus Plan at up to 35% of your base salary based on Company and individual achievement.  Your bonus will be based on your performance meeting established individual goals and objectives to support the growth strategy of the Company, as well as the Company’s overall performance.

	
 
	
•
	
Equity in the Company’s parent company, Harmony Biosciences II, Inc. (“Parent”) 400,000 stock options for Parent common stock at an exercise price equal to the greater of $1.00 and the fair market value per share of common stock as of your start date, to be determined by the Parent’s Board of Directors or its Compensation Committee, if applicable.

	
 
	
•
	
As a full-time Company employee, you will accrue paid vacation and sick leave.  Vacation will accrue at a rate of 1.25 days per month, or 15 days per year.

	
 
	
•
	
In consideration of the money left behind at your current employer for 2017 pro-rated annual bonus and LTI, you will receive a sign-on bonus of $100,000 (subject to applicable tax and other withholding), paid to you in two installments.  The first will be 50% ($50,000) and paid no later than 12/31/2017.  The second will be 50% ($50,000) and paid on 12/31/2018.  Both payments require that you are an active employee in good standing at the time of payment.  If you leave the company for any reason within 12 months after receiving the first payment or 6 months after receiving the second sign-on bonus payments, you must pay back the full pre-tax amount of that payment to Harmony Biosciences.

Harmony Biosciences, LLC 1033 Skokie Boulevard, Suite 600 • Northbrook, IL 60062

	
 
	
•
	
This offer is contingent upon successful completion of Harmony’s pre-employment process.

You will devote all of your time and attention to the Company (including, but not limited to, its business, operations and success) and shall not compete with the Company in any way during your employment.

 

As a full-time employee of the Company, except as expressly provided for above, you are eligible to participate in the provided Harmony Biosciences, LLC Employee Benefit Plans.

 

This offer of employment, if not previously accepted by you, will expire ten days after the date first set forth above.  This offer of employment does not represent an employment contract.  Just as you retain the right to resign, with or without notice or cause, Harmony Biosciences has the same right with respect to termination of your employment.  You will be an employee at will, and your employment is for no definite term, regardless of any other oral or written statement by any Harmony Biosciences officer or representative, with the exception of an express written employment contract signed by the CEO, President or Chief Legal Officer of the Company.  Notwithstanding anything in this offer of employment to the contrary, if your actual start date does not occur on or prior to October 2, 2017, this offer of employment will be null and void in its entirety (even if previously accepted by you).

 

If you understand and accept these terms, please sign and return one copy of this offer letter to me.  We would love to have you join Harmony Biosciences and be a part of building a great company.  Should you have any questions regarding this offer, please feel free to contact me at 847-715-0611.

 

Sincerely,

 

/s/ Anna Fenkanyn

 

Anna Fenkanyn

Human Resources

 

Agreed to and Accepted by:

 

	
/s/ Jeffrey Dierks
	
 
	
9/9/17

	
Jeffrey Dierks
	
 
	
Date

 

Harmony Biosciences, LLC 1033 Skokie Boulevard, Suite 600 • Northbrook, IL 60062Exhibit 10.1

 

FlexShopper, LLC

901 Yamato Road, Suite 260

Boca Raton, Florida 33431

 

March 22, 2021

 

122 Partners, LLC

	Attn.: 	Mr. Marc Malaga
	 	Managing Member

 

Re: Amendment No. 2 to Subordinated Debt
Financing Letter Agreement

 

Ladies and Gentlemen:

 

Reference is made to
the Subordinated Debt Financing Letter Agreement between us, dated January 25, 2019 (the “Letter Agreement”), and the
Subordinated Promissory Note in the principal amount of $1,000,000 issued by the Borrower to the Lender pursuant to the Letter
Agreement (the “Note”). All capitalized terms used herein without definition have the respective meanings ascribed
to them in the Letter Agreement.

 

This will confirm the
agreement of the Borrower and the Lender to amend the Letter Agreement and the Note as follows:

 

1.       
Extension of Note. Effective as of the date hereof, the Maturity Date of the Note is hereby extended through and including
April 1, 2022, unless accelerated by reason of an Event of Default.

 

2.       Representations
Remain True. In order to induce the Lender to effect the foregoing amendment, the Borrower hereby represents and warrants to
the Lender that all of the Borrower’s representations and warranties contained in the Note remain true and correct in all
material respects on and as of the date hereof, and all required consents in connection herewith have been obtained and are in
full force and effect.

 

3.       Remainder
of Documents Unmodified. Except as expressly set forth herein, all of the terms and conditions of the Letter Agreement and
the Note shall remain unmodified and in full force and effect. Nothing contained herein shall be deemed to constitute any agreement
of the Lender to effect any further amendments or modifications of the Letter Agreement or the Note at any time (whether of a similar
or different nature), or to grant to the Borrower any right to any further modification under or in respect of the Letter Agreement
and the Note.

 

     

     

    

 

 

4.       Miscellaneous.
The provisions contained under the caption “Miscellaneous” of the Letter Agreement are hereby incorporated herein mutatis
mutandis by this reference, and are expressly made applicable hereto.

 

Kindly confirm your
agreement to the foregoing by signing a counterpart copy hereof in the space provided below.

 

	 	Sincerely,
	 	 
	 	FLEXSHOPPER, LLC
	 	 
	 	By:	                     
	 	Name:	 
	 	Title:	 

 

	Acknowledged, Confirmed and Agreed to:
	 
	122 PARTNERS, LLC
	 
	By:	 	 
	Name:	Marc Malaga	 
	Title:	Managing MemberExhibit 10.2

 

FlexShopper, LLC

901 Yamato Road, Suite 260

Boca Raton, Florida 33431

 

March 22, 2021

 

NRNS Capital Holdings LLC

7809 Galleon Court

Parkland, Florida 33067

	Attn.:	Mr. Howard S. Dvorkin,
	 	Manager

 

		Re:	Amendment to NRNS Subordinated Debt Financing Commitment Letter

and Second Amended and Restated Subordinated Promissory Note

 

Ladies and Gentlemen:

 

Reference is made to
the Subordinated Debt Financing Commitment Letter, dated February 19, 2019 (the “Commitment Letter”), from NRNS Capital
Holdings LLC (the “Lender”) to FlexShopper, LLC (the “Borrower”), and the Second Amended and Restated Subordinated
Promissory Note, dated June 27, 2019 (the “Note”), made by Borrower in favor of Lender in the combined principal amounts
of $3,750,000, pursuant to the Commitment Letter. All capitalized terms used herein without definition have the respective meanings
ascribed to them in the Commitment Letter.

 

This will confirm the
agreement of the Borrower and the Lender to amend the Commitment Letter and the Note as follows:

 

1. Extension
of Note. Effective as of the date hereof, the date on which payments of principal and accrued interest shall be due and payable
by the Borrower is hereby extended from June 30, 2021 to April 1, 2022, unless accelerated by reason of an Event of Default and
not thereafter cured.

 

2. Representations
Remain True. In order to induce the Lender to effect the foregoing amendment, the Borrower hereby represents and warrants to
the Lender that all of the Borrower’s representations and warranties contained in Section 4 of the Note remain true and correct
in all material respects on and as of the date hereof, and all required consents in connection herewith have been obtained and
are in full force and effect.

 

3. Remainder
of Documents Unmodified. Except as expressly set forth herein, all of the terms and conditions of the Commitment Letter and
the Note shall remain unmodified and in full force and effect. Nothing contained herein shall be deemed to constitute any agreement
of the Lender to effect any further amendments or modifications of the Commitment Letter or the Note at any time (whether of a
similar or different nature), or to grant to the Borrower any right to any further modification under or in respect of the Commitment
Letter and the Note.

 

     

     

    

 

4. Miscellaneous.
The provisions contained under the caption “Miscellaneous” of the Commitment Letter are hereby incorporated herein
mutatis mutandis by this reference, and are expressly made applicable hereto.

 

Kindly confirm your
agreement to the foregoing by signing a counterpart copy hereof in the space provided below.

 

	 	Sincerely,
	 	 
	 	FLEXSHOPPER, LLC
	 	 
	 	By:	       
	 	Name:	 
	 	Title:	 

 

	Acknowledged, Confirmed and Agreed to:
	 
	NRNS CAPITAL HOLDINGS LLC
	 
	By:	 	 
	Name: 	Howard S. Dvorkin	 
	Title:	Manager

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00325-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00325-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00325-of-00352.parquet"}]]